Stroke
Serviço de Neurologia, Hospital de Santa Maria, Av Prof. Egas Moniz, 1649-035 Lisboa, Portugal.
Published: September 2010
Background And Purpose: After cerebral vein and dural sinus thrombosis (CVT), there is an increased risk of further venous thromboembolic events (VTEs). Time to a second cerebral or systemic venous thrombotic event and risk factors for recurrence have not been investigated in large prospective studies.
Methods: We used the International Study on Cerebral Vein and Dural sinus Thrombosis, which included 624 patients with CVT followed up for a median of 13.9 months. Outcome measures included all symptomatic VTEs and CVT recurrence. Potential predictors of recurrence, including demographic characteristics, imaging features, thrombophilic abnormalities, other risk factors for CVT, and anticoagulation, were analyzed by Cox survival analysis.
Results: Of the 624 included patients, 36 (5.8%) had at least 1 venous thromboembolic event. The rate of VTEs after the initial CVT was 4.1 per 100 person-years. Of all VTEs, 63.2% (n=24) occurred within the first year. Fourteen patients (2.2%) had an episode of recurrent CVT and the rate of recurrence was 1.5 per 100 person-years. Nine (64.3%) of these CVT recurrences occurred within the first year. Male gender (hazard ratios=2.6; 95% CI, 1.4 to 5.1; P=0.004) and polycythemia/thrombocythemia (hazard ratios=4.4; 95% CI, 1.6 to 12.7; P=0.005) were the only factors associated with a significant higher risk of VTEs in multivariate survival analysis.
Conclusions: The risk of recurrence of CVT is low but is moderate for other VTEs. Recurrence of venous thrombosis after CVT is more frequent among men and in patients with polycythemia/thrombocythemia.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1161/STROKEAHA.110.581223 | DOI Listing |
Eur J Haematol
January 2025
Venous Thromboembolism Unit, Internal Medicine Department, General University Hospital Gregorio Marañón, Madrid, Spain.
Introduction: Anticoagulant therapy is critical for venous thromboembolism (VTE) management, though bleeding remains a major concern, ranging from mild to fatal events. This study aimed to assess the predictive value of cytokines for major bleeding in patients with acute pulmonary embolism (PE).
Methods: In this prospective, observational study, patients aged ≥ 18 years with acute PE were enrolled from April 2021 to September 2022 and followed for 30 days.
Thromb J
January 2025
College of engineering and computer sciences, Jazan University, Jazan, Saudi Arabia.
Venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE), continues to pose significant clinical challenges despite advancements in medical care. Artificial intelligence (AI) presents promising opportunities to enhance the diagnosis, prediction, and management of VTE. This review examines the transformative potential of AI in thrombosis care, highlighting both the potential benefits and the challenges that need to be addressed.
View Article and Find Full Text PDFThromb Res
January 2025
Clinical Investigation Center CIC-EC 1408, University Hospital of Saint-Etienne, France; SAINBIOSE, UMR 1059, INSERM, Jean Monnet University, Saint-Etienne, France; Division of Clinical Hematology, University Hospital of Saint-Etienne, France. Electronic address:
Background: Candidate biomarkers to improve venous thromboembolism (VTE) risk prediction in patients with newly diagnosed multiple myeloma (MM) undergoing anti-myeloma therapy include tissue factor-bearing microvesicles (MV-TF), procoagulant phospholipids (procoag-PPL), and D-dimer.
Objective: We aimed to determine the levels of MV-TF, procoag-PPL, and D-dimer at baseline and during initial anti-myeloma therapy and their association with the risk of VTE.
Methods: This prospective, longitudinal, observational study included 71 patients with newly diagnosed MM who were eligible for anti-myeloma therapy.
J Am Acad Orthop Surg Glob Res Rev
January 2025
From the Department of Orthopaedics and Rehabilitation, Yale School of Medicine, New Haven, CT.
Introduction: Venous thromboembolism (VTE) following injury and subsequent fixation of a distal femur fracture (DFFx) is associated with considerable morbidity. However, the incidence of VTE, associated factors, and the relative risk compared with hip fracture (HFx) fixation remains poorly characterized.
Methods: Retrospective cohort study using the PearlDiver M165 database to identify geriatric patients who underwent DFFx and HFx fixation.
Thromb Haemost
January 2025
Guy's and St Thomas' NHS Foundation Trust, King's College London, United Kingdom.
Background: The benefits and risks of extending anticoagulant treatment beyond the first 3 to 6 months in patients with venous thromboembolism (VTE) in clinical practice are not well understood.
Methods: ETNA-VTE Europe is a prospective, noninterventional, post-authorization study in unselected patients with VTE treated with edoxaban in eight European countries for up to 18 months. Recurrent VTE, major bleeding, and all-cause death were the primary study outcomes.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!
© LitMetric 2025. All rights reserved.